Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

by

8 posts
RRoche
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-22
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…
NNovartis
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Read More

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

  • 2026-03-29
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
NNovartis
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
Read More

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

  • 2026-03-27
– Acquisition brings together Excellergy’s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of…
NNovartis
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Read More

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

  • 2026-03-06
Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹…
BBern
Bern's modern Swiss design and pine cone-inspired facade (Artist's perspective)
Read More

Manila Bulletin – Bern by Brittany answers the demand for luxury mountain living

  • 2026-03-01
The chill vibe of Baguio City had always been a welcome respite from the heat and hustle of…
GGeneva
US Sanctions Iranian Oil Exports ahead of Geneva Talks
Read More

US Sanctions Iranian Oil Exports ahead of Geneva Talks

  • 2026-02-26
Islam Times – The U.S. Treasury Department on Wednesday imposed new Iran-related sanctions on four individuals, several entities…
AAlps
Ten skiers missing in California avalanche, after three killed by two snowslides in French Alps
Read More

Ten skiers missing in California avalanche, after three killed by two snowslides in French Alps

  • 2026-02-18
Meanwhile, avalanches continue to be deadly this winter in Europe. Two avalanches killed at least three people in…
GGeneva
Reuters claims about holding Iran-US talks in Geneva
Read More

Reuters claims about holding Iran-US talks in Geneva

  • 2026-02-14
Afghan Voice Agency (AVA) – International Service: Reuters news agency wrote this morning (Saturday, February 14) citing a…
Switzerland
www.europesays.com